Dr. Tagawa and colleagues presented the sacituzumab data in patients with advanced urothelial cancer, and these were predominantly a heavy pretreated patient population. Thirty-eight percent of those patients had actually received prior checkpoint inhibitors and demonstrated promising response rate of 31% as well as responses in patients who were previously treated with checkpoint inhibitors and patients with visceral metastatic disease, including liver metastases with responses in about a third of patients, which we know historically is a very difficult patient population to treat...
Dr. Tagawa and colleagues presented the sacituzumab data in patients with advanced urothelial cancer, and these were predominantly a heavy pretreated patient population. Thirty-eight percent of those patients had actually received prior checkpoint inhibitors and demonstrated promising response rate of 31% as well as responses in patients who were previously treated with checkpoint inhibitors and patients with visceral metastatic disease, including liver metastases with responses in about a third of patients, which we know historically is a very difficult patient population to treat.
There was some durability to those responses, and toxicity was present. There was gastrointestinal toxicity, most notably diarrhea, in about 70% of patients. There was also issues related to nausea, some fatigue, and then myelosupression, 38% grade 3-4 with a 7% febrile neutropenia rate. So, I think you need to be thoughtful about the type of patient that you’re treating in understanding what the toxicity profile is to know whether or not it’s best to apply that particular drug to that particular patient.